Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. - Wikidata - wikimedia - TriplyDB

Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

http://www.wikidata.org/entity/Q36929605

about

Unraveling insulin-like growth factor binding protein-3 actions in human disease Hyperglycemia and insulin resistance and the risk of BPH/LUTS: an update of recent literature A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men.Linking pre-diabetes with benign prostate hyperplasia. IGFBP-3: a conductor of benign prostate hyperplasia development orchestra?Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma.Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention.PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.Radiation induced non-targeted response: mechanism and potential clinical implications.Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.What Are the Links of Prostate Cancer with Physical Activity and Nutrition? : A Systematic Review Article Review of exercise and the risk of benign prostatic hyperplasia.Benign prostatic hyperplasia: does lifestyle play a role?A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?Lower urinary tract symptoms in relation to region of birth in 95,393 men living in Australia: the 45 and Up Study.Metabolic Syndrome and Lower Urinary Tract Symptoms: Epidemiological Study.TARGETED AND OFF-TARGET (BYSTANDER AND ABSCOPAL) EFFECTS OF RADIATION THERAPY: REDOX MECHANISMS AND RISK-BENEFIT ANALYSIS.Office evaluation of male patients with lower urinary tract symptoms.Flaxseed suppressed prostatic epithelial proliferation in a rat model of benign prostatic hyperplasia.

P2860

Q24650060-C9CD7F4E-9A64-4FB4-AFF2-A3FA1652C6A1 Q27011347-3F682EC3-4415-459A-BEA7-8931465A1D62 Q31049602-C6295ECF-9B88-4251-90D9-4790089701DD Q33416685-054D5457-04FB-4E82-A7CE-8689CA574F3D Q33725858-874A90A4-48A8-4696-82E0-D33A9FC30E83 Q33741548-3D664B60-EE12-42B3-AFE5-DF152012AB28 Q34493142-AF1E8D22-CF83-4879-9762-31E71F5B5955 Q35075205-5777CD80-B549-4784-B50D-85DDB2885C99 Q35098547-9FA91776-B278-4DD2-9FDC-566A080BDDF3 Q35182377-8955994B-0B0F-45A2-9F25-AB10A759B215 Q35216293-D9969493-F40F-468B-BB57-C67403116C05 Q35973897-810A46ED-D572-4B72-8450-7742E3CE20B0 Q37127902-D5EEDF51-5D00-472A-9717-DBE8AC4BFA42 Q37305883-674FE5BA-E94A-4DA7-BE55-99CB29FC9469 Q37551308-D3327175-4379-432E-8C72-961F9CA148B5 Q37667615-6BCF25B9-FEFC-4ABF-96A6-BDEFD9E4A95A Q37667643-7445D6A0-4799-4229-802E-ED15B5DBF6A4 Q38171391-19831030-9690-438B-A2D9-F319E706ACB6 Q38786798-F786FCD1-E428-45D5-AE8C-79E153A8C9C9 Q39162041-99E746EB-BA34-4930-84F8-858D921B0268 Q40202608-FF5DF267-6C4E-47A1-8D91-6F105C4FA96E Q47558991-379F6451-36E1-4A9F-8B2E-10307F97F362 Q51317315-8A898724-6B27-40AE-9D7E-3102F332DC39 Q52958024-6ED1F6C9-33A9-4A5B-9021-8AC0000B8D2C

P2860

Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.

http://www.wikidata.org/entity/Q36929605

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Insulin-like growth factor-I, ...... state cancer prevention trial.

@en

type

label

Insulin-like growth factor-I, ...... state cancer prevention trial.

@en

prefLabel

Insulin-like growth factor-I, ...... state cancer prevention trial.

@en

P1433

Q36929605-D142FC78-5A05-4276-BDC1-45C4A94A52A3

P1476

Q36929605-3066EF7C-F723-4E85-9126-658E3C5B4855

P2093

Q36929605-07053867-CDF0-4110-A55C-17FAA91441A8

Q36929605-3A43652A-8C01-4872-B6F6-91876F2F3B3D

Q36929605-3CC5DD20-92AB-4F06-9CA9-9C0F8D134832

Q36929605-7BD1E101-238F-409D-96F4-BD58F9BB29BC

Q36929605-B8C05372-CC1D-4A10-B782-1427A7D87253

Q36929605-CA945C9C-CABA-438C-90DA-9146767CFFF2

Q36929605-CF63C1C0-C47B-48FB-A9CE-CFBBA9E50B49

P2860

Q36929605-0400F9AA-79D6-4519-BC05-1944754891F1

Q36929605-0ADDB9F8-7B4D-4BF0-84FD-43310B8F7472

Q36929605-140E68A4-3018-468E-9E36-43E0FD4A27F2

Q36929605-2FE3D682-592C-4882-869D-EB93D8C34250

Q36929605-4F61E9E9-8C04-4C32-80CC-691190E1764A

Q36929605-4FAE1E22-99E8-4F0F-8609-71EBFF30E585

Q36929605-51FFB8B3-FCFB-4B7B-8D4D-783938FEF822

Q36929605-5616B469-1A4F-42BA-BC3D-E26711A2DCF1

Q36929605-5767BB20-D762-4E4C-AE2B-D5D28E5C67A8

Q36929605-5DEA5C07-6F6F-4863-B1DA-B7411307D2B5

P304

Q36929605-51BE9D06-FE3E-4E15-BEEE-291D62C88F8A

P31

Q36929605-454074CE-74A0-400F-92E5-3AA35D8B9693

P356

Q36929605-CAD07771-3A30-4D27-8326-870A3E83D93B

P433

Q36929605-6FAEA649-BCF6-43B5-93C4-5FAFDF404A20

P478

Q36929605-FCC65793-7B3C-4BDC-80A9-118678B10B0D

P50

Q36929605-324B60BC-D72F-476B-8B87-6DE1A3C45E98

Q36929605-6B3855D0-DF1B-4836-BFBF-448CDA0E0348

P577

Q36929605-670299E3-6BAA-4817-9351-3FC4EA52FBC6

P5875

Q36929605-0D5767BF-FE35-4A24-804D-B39DE702098B

P698

Q36929605-04DD22C0-64F7-483C-9528-512A3C132DA6

P932

Q36929605-91AB2DE2-6E37-4236-9200-A9BE33278A96

P356

P1433

P1476

Insulin-like growth factor-I, ...... state cancer prevention trial.

@en

P2093

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

Jeannette Schenk

http://www.w3.org/2001/XMLSchema#string

Marian L Neuhouser

http://www.w3.org/2001/XMLSchema#string

Michael Pollak

http://www.w3.org/2001/XMLSchema#string

Phyllis J Goodman

http://www.w3.org/2001/XMLSchema#string

Yoon Ju Song

http://www.w3.org/2001/XMLSchema#string

P2860

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Role of the insulin-like growth factor family in cancer development and progression.

Pathology of benign prostatic hyperplasia.

Insulin-like growth factors and neoplasia.

Nutritional regulation of the insulin-like growth factors.

The influence of finasteride on the development of prostate cancer.

Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans.

Prostatic hyperplasia: an unknown feature of acromegaly.

P304

1477-1486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.20819

http://www.w3.org/2001/XMLSchema#string

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Alan R. Kristal

David F. Penson

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5233346

http://www.w3.org/2001/XMLSchema#string

P698

18618736

http://www.w3.org/2001/XMLSchema#string

P932

2564287

http://www.w3.org/2001/XMLSchema#string